Overview

• A Norwegian cohort study followed 26,210 pregnancies and assessed children for neurodevelopmental disorders up to 14 years of age.
• The research found no increased risk of autism, ADHD, or other disorders in children exposed to triptans before or during pregnancy.
• Four distinct exposure groups were analyzed based on triptan use patterns, with robust adjustments for confounding factors like parental health history and folic acid intake.
• The study highlights the safety of treating migraines with triptans during pregnancy, addressing concerns about maternal and fetal health risks.
• A limitation noted was the reliance on prescription data, which may not fully reflect actual medication ingestion.